Key result
Myocardial infarction was associated with increased platelet aggregation, elevated thromboxane B and prostacyclin production, and significant platelet resistance to prostacyclin during the first month.
Observational
The study demonstrates dynamic changes in platelet reactivity and prostacyclin sensitivity in the first month post-MI, providing a pathophysiological rationale for early and sustained antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
Supports early post-MI platelet monitoring; hypothesis-generating for resistance-targeted therapy and should not yet change practice.
This study was designed to investigate platelet aggregation, plasma thromboxane A, and prostacyclin concentration and platelet sensitivity to prostacyclin simultaneously during the first month after myocardial infarction (MI). Spontaneous platelet aggregation and aggregation responses to ADP and adrenaline were low on the day of admission, increased rapidly by the 7th day post-MI, remained elevated during the second week post-MI and reached the level of chronic coronary artery disease patients but not healthy persons at the end of the fourth week of illness. An increase in plasma thromboxane B, the spontaneous and stable breakdown product of thromboxane A, level and enhanced prostacyclin production, with a maximum on the third post-MI day, were observed. We also demonstrated a significant platelet resistance to prostacyclin in MI patients. Thrombocyte sensitivity to prostacyclin normalized by the end of the fourth post-MI week. These results indicate the need for therapy with platelet inhibitors in patients with MI.
No takes yet. Share an insight, caveat, or question.
Viigimaa et al. (1995) conducted an observational in Myocardial Infarction. Myocardial infarction vs. Chronic coronary artery disease patients and healthy persons was evaluated on Platelet aggregation, plasma thromboxane A, prostacyclin concentration, and platelet sensitivity to prostacyclin. Myocardial infarction was associated with increased platelet aggregation, elevated thromboxane B and prostacyclin production, and significant platelet resistance to prostacyclin during the first month.
Synapse has enriched 10 related papers. Consider them for comparative context: